[{"id":"6c31d924-416a-4fac-90f3-4e9e04970c2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04708470","created_at":"2021-01-19T20:51:59.772Z","updated_at":"2025-02-25T12:27:53.092Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers","source_id_and_acronym":"NCT04708470","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jingzhuda (entinostat) • bintrafusp alfa (M7824) • PDS01ADC"],"overall_status":"Recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 10/05/2021","start_date":" 10/05/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-24"},{"id":"4cfc5715-dc42-47d6-8b29-f4162141b070","acronym":"20-C-0012","url":"https://clinicaltrials.gov/study/NCT04235777","created_at":"2021-01-29T07:20:15.829Z","updated_at":"2025-02-25T13:40:02.108Z","phase":"Phase 1","brief_title":"Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies","source_id_and_acronym":"NCT04235777 - 20-C-0012","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • PDS01ADC"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-21"},{"id":"1bb11f50-7b59-4eb4-901f-d7b6ac9b157d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04287868","created_at":"2021-01-18T20:48:45.296Z","updated_at":"2025-02-25T14:07:41.725Z","phase":"Phase 1/2","brief_title":"Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies","source_id_and_acronym":"NCT04287868","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CDKN2A • CD4","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1 • CDKN2A • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • Versamune HPV • PDS01ADC"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 06/09/2020","start_date":" 06/09/2020","primary_txt":" Primary completion: 07/26/2022","primary_completion_date":" 07/26/2022","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-19"},{"id":"ca63580a-c74e-4b79-b0d5-8d419247f75b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03177291","created_at":"2021-01-18T15:40:02.831Z","updated_at":"2025-02-25T14:15:00.298Z","phase":"Phase 1","brief_title":"Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC","source_id_and_acronym":"NCT03177291","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 09/26/2017","start_date":" 09/26/2017","primary_txt":" Primary completion: 05/09/2021","primary_completion_date":" 05/09/2021","study_txt":" Completion: 12/04/2024","study_completion_date":" 12/04/2024","last_update_posted":"2025-02-18"},{"id":"930271d4-4c89-4b12-9340-38647392d747","acronym":"","url":"https://clinicaltrials.gov/study/NCT05732961","created_at":"2023-02-17T15:00:52.691Z","updated_at":"2025-02-25T14:17:40.080Z","phase":"Phase 2","brief_title":"Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms","source_id_and_acronym":"NCT05732961","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" SF3B1","pipe":" | ","alterations":" SF3B1 mutation","tags":["SF3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Reblozyl (luspatercept-aamt)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 02/21/2023","start_date":" 02/21/2023","primary_txt":" Primary completion: 06/20/2025","primary_completion_date":" 06/20/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-07"},{"id":"ba15135a-7176-4f0e-a8cc-e6c040cf6509","acronym":"","url":"https://clinicaltrials.gov/study/NCT04574583","created_at":"2021-01-18T21:50:28.241Z","updated_at":"2025-02-25T17:00:40.932Z","phase":"Phase 1/2","brief_title":"Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta \"Trap\"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)","source_id_and_acronym":"NCT04574583","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PD-L1 • ER • PGR • CD4","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • SX-682 • Panvac-VF (falimarev/inalimarev)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 11/24/2020","start_date":" 11/24/2020","primary_txt":" Primary completion: 02/07/2023","primary_completion_date":" 02/07/2023","study_txt":" Completion: 05/19/2023","study_completion_date":" 05/19/2023","last_update_posted":"2025-02-03"},{"id":"d78d7b46-d2cc-485a-8c04-81f9d73189d4","acronym":"KEYNOTE-E28","url":"https://clinicaltrials.gov/study/NCT04429542","created_at":"2021-01-18T21:20:02.191Z","updated_at":"2025-02-25T16:10:23.024Z","phase":"Phase 1","brief_title":"Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors","source_id_and_acronym":"NCT04429542 - KEYNOTE-E28","lead_sponsor":"Bicara Therapeutics","biomarkers":" PD-L1","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • KRAS G12D • EGFR amplification • PD-L1 negative • RAS wild-type • KRAS G12 • KRAS G13 • EGFR negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • KRAS G12D • EGFR amplification • PD-L1 negative • RAS wild-type • KRAS G12 • KRAS G13 • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ficerafusp alfa (BCA101)"],"overall_status":"Recruiting","enrollment":" Enrollment 292","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-01-27"},{"id":"50e34af4-899e-42bc-acc2-0b1a7ae0ee45","acronym":"CRB-601-01","url":"https://clinicaltrials.gov/study/NCT06603844","created_at":"2025-02-26T08:20:15.107Z","updated_at":"2025-02-26T08:20:15.107Z","phase":"Phase 1/2","brief_title":"First-in-human Study of CRB-601-01 to Treat Patients with Advanced Solid Tumor.","source_id_and_acronym":"NCT06603844 - CRB-601-01","lead_sponsor":"Corbus Pharmaceuticals Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CRB-601"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 12/04/2024","start_date":" 12/04/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-12-24"},{"id":"688f7919-86e0-4ff0-8b2a-5d36de39804f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06487624","created_at":"2025-02-26T10:01:41.524Z","updated_at":"2025-02-26T10:01:41.524Z","phase":"Phase 1","brief_title":"An Engineered Sirpα Fused to Anti-Pd-L1 and Tgf-β Fusion Protein (HCB301) in Subjects with Selected Advanced Tumors","source_id_and_acronym":"NCT06487624","lead_sponsor":"FBD Biologics Limited","biomarkers":" TGFB1","pipe":"","alterations":" ","tags":["TGFB1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 01/30/2025","start_date":" 01/30/2025","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2024-12-11"},{"id":"773c9389-65d5-4b78-bd5e-1b126199a8e4","acronym":"LUNG 037","url":"https://clinicaltrials.gov/study/NCT03631706","created_at":"2021-01-17T17:55:02.468Z","updated_at":"2025-02-25T16:08:13.876Z","phase":"Phase 3","brief_title":"M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT03631706 - LUNG 037","lead_sponsor":"EMD Serono Research \u0026 Development Institute, Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • bintrafusp alfa (M7824)"],"overall_status":"Completed","enrollment":" Enrollment 304","initiation":"Initiation: 10/01/2018","start_date":" 10/01/2018","primary_txt":" Primary completion: 06/07/2021","primary_completion_date":" 06/07/2021","study_txt":" Completion: 06/25/2024","study_completion_date":" 06/25/2024","last_update_posted":"2024-08-13"},{"id":"7258fe47-fdbb-4505-b15b-20957550273b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04303117","created_at":"2021-01-18T20:52:07.511Z","updated_at":"2024-07-02T16:34:26.828Z","phase":"Phase 1/2","brief_title":"NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma","source_id_and_acronym":"NCT04303117","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide • bintrafusp alfa (M7824) • PDS01ADC"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-06-12"},{"id":"b4b55ef9-4653-42bf-95e0-84efd373e033","acronym":"","url":"https://clinicaltrials.gov/study/NCT05891249","created_at":"2023-06-06T14:07:08.438Z","updated_at":"2024-07-02T16:34:26.950Z","phase":"Phase 4","brief_title":"A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) \u0026 Beta-thalassemia (β-Thal) in India","source_id_and_acronym":"NCT05891249","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" SF3B1","pipe":" | ","alterations":" SF3B1 mutation","tags":["SF3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Reblozyl (luspatercept-aamt)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/05/2023","start_date":" 06/05/2023","primary_txt":" Primary completion: 04/13/2026","primary_completion_date":" 04/13/2026","study_txt":" Completion: 04/13/2026","study_completion_date":" 04/13/2026","last_update_posted":"2024-06-12"},{"id":"786f4600-19b5-4661-828d-06dd8c75ce47","acronym":"QuEST1","url":"https://clinicaltrials.gov/study/NCT03493945","created_at":"2021-12-08T18:56:16.054Z","updated_at":"2024-07-02T16:34:37.137Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)","source_id_and_acronym":"NCT03493945 - QuEST1","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • BRCA1 • BRCA2 • MSI • HRD","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR","tags":["TMB • BRCA1 • BRCA2 • MSI • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • epacadostat (INCB024360) • Anktiva (nogapendekin alfa inbakicept-pmln)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 05/01/2018","start_date":" 05/01/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-07"},{"id":"58c294f2-ab5b-419e-afe1-53ffc8ada05f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05012098","created_at":"2021-08-19T15:53:00.327Z","updated_at":"2024-07-02T16:34:38.100Z","phase":"Phase 2","brief_title":"Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).","source_id_and_acronym":"NCT05012098","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":"","alterations":" ","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 06/21/2022","start_date":" 06/21/2022","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2024-06-05"},{"id":"929ccfce-1289-4064-963b-ead111a6575c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04835896","created_at":"2021-04-08T13:52:37.167Z","updated_at":"2024-07-02T16:35:05.912Z","phase":"Phase 1/2","brief_title":"Study of M7824 and Paclitaxel Combination as a Second-line Treatment in Patients With Recurrent/Metastatic Gastric Cancer","source_id_and_acronym":"NCT04835896","lead_sponsor":"Yonsei University","biomarkers":" HER-2 • CD4","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • bintrafusp alfa (M7824)"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 06/02/2021","start_date":" 06/02/2021","primary_txt":" Primary completion: 10/27/2023","primary_completion_date":" 10/27/2023","study_txt":" Completion: 10/27/2023","study_completion_date":" 10/27/2023","last_update_posted":"2024-05-06"},{"id":"17124774-125f-48f3-9fa4-bdffab757f3c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06300463","created_at":"2024-03-12T14:20:52.081Z","updated_at":"2024-07-02T16:35:09.965Z","phase":"Phase 2","brief_title":"Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases","source_id_and_acronym":"NCT06300463","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e balstilimab (AGEN2034) • botensilimab (AGEN1181) • dalutrafusp alfa (AGEN1423)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 03/26/2024","start_date":" 03/26/2024","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-04-12"},{"id":"b7dbd59d-0e5c-48d1-85e5-f28fb24a008f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05445882","created_at":"2022-07-06T14:54:26.168Z","updated_at":"2024-07-02T16:35:11.811Z","phase":"Phase 2","brief_title":"N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer","source_id_and_acronym":"NCT05445882","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • Anktiva (nogapendekin alfa inbakicept-pmln)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2024-04-02"},{"id":"fffc67bb-7fbb-40b0-9b45-301133ae28bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04984668","created_at":"2021-07-30T17:55:12.603Z","updated_at":"2024-07-02T16:35:19.910Z","phase":"Phase 1/2","brief_title":"A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors","source_id_and_acronym":"NCT04984668","lead_sponsor":"Suzhou Kintor Pharmaceutical Inc,","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erfonrilimab (KN046) • ascrinvacumab (GT90001)"],"overall_status":"Recruiting","enrollment":" Enrollment 216","initiation":"Initiation: 11/02/2021","start_date":" 11/02/2021","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-02-09"},{"id":"a442140a-cf73-49ad-8943-04880441287b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06223308","created_at":"2024-01-25T16:19:06.568Z","updated_at":"2024-07-02T16:35:22.215Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT06223308","lead_sponsor":"Shanghai Huaota Biopharmaceutical Co., Ltd.","biomarkers":" PD-L1 • TGFB1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 09/09/2022","start_date":" 09/09/2022","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-01-25"},{"id":"c58e3326-117a-4070-8ee0-1eaeb05b85fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04951947","created_at":"2021-07-07T12:53:42.327Z","updated_at":"2024-07-02T16:35:25.158Z","phase":"Phase 2","brief_title":"JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer","source_id_and_acronym":"NCT04951947","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • JS201"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-12-27"},{"id":"cdf035f3-57bf-43f0-9cb5-ab0631b1c1bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04756505","created_at":"2021-02-16T12:53:52.608Z","updated_at":"2024-07-02T16:35:25.096Z","phase":"Phase 1","brief_title":"Immunotherapy (NHS-IL12 \u0026 Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial","source_id_and_acronym":"NCT04756505","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • PGR expression","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • PDS01ADC"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/07/2021","start_date":" 03/07/2021","primary_txt":" Primary completion: 02/16/2022","primary_completion_date":" 02/16/2022","study_txt":" Completion: 02/16/2022","study_completion_date":" 02/16/2022","last_update_posted":"2023-12-27"},{"id":"2365a87d-8e35-400d-9a3b-2c370f444652","acronym":"20-C-0104","url":"https://clinicaltrials.gov/study/NCT04432597","created_at":"2021-01-29T07:20:51.032Z","updated_at":"2024-07-02T16:35:28.048Z","phase":"Phase 1/2","brief_title":"HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers","source_id_and_acronym":"NCT04432597 - 20-C-0104","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" TILs","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • PRGN-2009"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 08/11/2020","start_date":" 08/11/2020","primary_txt":" Primary completion: 11/22/2022","primary_completion_date":" 11/22/2022","study_txt":" Completion: 11/20/2025","study_completion_date":" 11/20/2025","last_update_posted":"2023-11-27"},{"id":"4242d42f-1cfe-4a23-8b8a-fa1b890bd61f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06142318","created_at":"2023-11-21T20:17:40.195Z","updated_at":"2024-07-02T16:35:28.502Z","phase":"Phase 2","brief_title":"Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT06142318","lead_sponsor":"Nanfang Hospital, Southern Medical University","biomarkers":" TMB","pipe":" | ","alterations":" PD-L1 expression","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 11/15/2023","start_date":" 11/15/2023","primary_txt":" Primary completion: 01/30/2025","primary_completion_date":" 01/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-11-21"},{"id":"ea35f30d-6ff9-4dfc-b85a-2601e3cf6973","acronym":"MS200647_0047","url":"https://clinicaltrials.gov/study/NCT03833661","created_at":"2021-01-18T18:55:43.816Z","updated_at":"2025-02-25T16:08:52.588Z","phase":"Phase 2","brief_title":"M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)","source_id_and_acronym":"NCT03833661 - MS200647_0047","lead_sponsor":"EMD Serono Research \u0026 Development Institute, Inc.","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824)"],"overall_status":"Completed","enrollment":" Enrollment 159","initiation":"Initiation: 03/26/2019","start_date":" 03/26/2019","primary_txt":" Primary completion: 11/09/2020","primary_completion_date":" 11/09/2020","study_txt":" Completion: 09/30/2022","study_completion_date":" 09/30/2022","last_update_posted":"2023-10-25"}]